A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
Ontology highlight
ABSTRACT: The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced owing to emerging variants of concern1,2. Development of host-directed therapeutics and prophylactics could limit such resistance and offer urgently needed protection against variants of concern3,4. Attractive pharmacological targets to impede viral entry include type-II transmembrane serine proteases (TTSPs) such as TMPRSS2; these proteases cleave the viral spike protein to expose the fusion peptide for cell entry, and thus have an essential role in the virus lifecycle5,6. Here we identify and characterize a small-molecule compound, N-0385, which exhibits low nanomolar potency and a se
SUBMITTER: Shapira T
PROVIDER: S-EPMC9095466 | biostudies-literature | 2022 May
REPOSITORIES: biostudies-literature
ACCESS DATA